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A B S T R A C T
This article explores recent advances in the development of electrochemical biosensors on microneedle platforms
towards on-device sensing of biomarkers present in dermal interstitial fluid. The integration of a biosensor with a
microneedle platform opens the possibility for minimally invasive bio-chemical detection or continuous mon-
itoring within the dermal interstitial fluid. An introduction to interstitial fluid is provided placing emphasis on
sampling methods that have been employed to extract and/or sample tissue fluid for analysis. We look briefly at
microneedle technologies used to extract dermal interstitial fluid for subsequent analysis. Successive content will
focus on microneedle technologies which have been integrated with electrochemical biosensors for the quan-
tification of various metabolites, electrolytes and other miscellaneous entities known to be present in the dermal
interstitial fluid. The review concludes with some of the key challenges and opportunities faced by this next-
generation wearable sensing technology.
1. Introduction
Developments in wearable sensing technologies are becoming in-
creasingly popular owing to their potential contribution to human
health, performance and personalized medicine [1–3]. Those that are
commercially available are mainly limited to measuring a real-time
electrophysiological response. Electrophysiological parameters such as
EEG (electroencephalography), ECG (electrocardiography) and EMG
(electromyography), pulse oximetry and body temperature are some
examples of physiological monitoring that can be measured with cur-
rent wearable devices [4–6]. Previous reviews have described current
developments in wearable sensor technologies covering aspects on
fabrication [7], materials and systems [8], electrophysiological wear-
ables [9], flexible wearables and electronics [10] sensors and electro-
chemical sensors [11], sweat monitoring [12], wireless and commu-
nications [13] as well as energy harvesting developments [14].
Conversely, this review explores advances specific to electrochemical
sensors integrated with microneedles which are designed to interface
with dermal interstitial fluid (ISF). Despite the tremendous growth in
wearable sensor platforms, to date, there are a limited number of
commercially available wearable devices capable of detecting or mon-
itoring biomolecules [15]. Continuous glucose monitoring systems
(CGM's) such as the Dexcom, Freestyle Libre and the Minimed are, to
the best of the authors' knowledge, the only wearable devices on the
market capable of monitoring at a molecular level [16]. These devices
are described as minimally-invasive as the sensing element is inserted a
couple of millimetres underneath the skin. Microneedles pose as an
attractive wearable platform for molecular detection or monitoring as
they have been integrated with biosensors capable of detecting meta-
bolites, electrolytes and other clinically relevant targets. These devices
differ from the current mini-needle devices as they are typically de-
signed to extend no more than 1 mm into the skin potentially offering a
less painful alternative [17,18]. This review is concerned specifically
with microneedle technologies which have been fabricated to carry out
bio-chemical measurements of various physiologically relevant targets
present in the dermal ISF. Diagnostic testing for the presence of disease,
whether of the genetic or infectious type is commonly performed
through analysis of bio-fluids such as blood, urine and saliva [19].
Samples are collected from the patient and sent to a lab for analytical
testing. ISF has received interest for the detection of analytes [20],
biomarkers [21,22] metabolites [23] and drugs [24,25]. In particular,
dermal or subcutaneous ISF is desirable as a medium for measuring
physiological information in order to avoid repetitive blood extraction
from patients [26]. Dermal or subcutaneous ISF can be accessed
through the skin [25,27–29], however extraction techniques are not
feasible for clinical use. Blood can be drawn directly from a patient in
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T
less than 3 min, by contrast, ISF extraction reports have listed various
waiting times; from 10 min up to a number of hours. ISF extraction also
yields low sample volumes depending on the device and method of
extraction [30–32]. As a result, microneedles, which can directly in-
terface electrochemical sensors with dermal ISF are being developed as
wearable devices for bio-chemical based detection [33–35]. A con-
ceptualisation of the use of solid microneedles for electrochemical de-
tection within the dermal interstitium is depicted in Fig. 1. To gain a
greater understanding of the potential for utilizing the interstitial space
for wearable monitoring, this review will initially describe the ISF from
a minimally invasive device perspective, and then focus on a number of
research efforts which have accessed the fluid for molecular analysis.
Later the review will highlight the role microneedles have played in
accessing dermal tissue fluid as well as their integration with electro-
chemical sensors for detection and/or monitoring. Finally, the current
status and the future perspective for these platforms will be sum-
marised.
2. Interstitial fluid
Body fluid contents are broadly categorized either as extracellular
fluid, i.e. the fluid surrounding all of the cells in the body, or in-
tracellular fluid, i.e. the fluid contained within the cells in the body
[36]. ISF, along with plasma, makes up the extracellular fluid en-
vironment. Fig. 2 depicts the distribution of water in the human body;
the average human holds somewhere between 9 and 13.5 L of ISF
[37,38].
Concepts on fluid filtration date back to the 1980s when Starling
discovered that fluid injected into the interstitial space of a dog limb
was present in venous blood [40]. Since then many advances in the
understanding of fluid transport and the physiology of microvascular
exchange have been well documented [41–44]. Fig. 3 illustrates fluid
movement from the blood plasma through the endothelial cell wall in to
the interstitial compartment/interstitium (region between the vascu-
lature and cells) where it can access the lymphatic vasculature and
return to the blood. Three paths exist for analytes to enter the inter-
stitial fluid: firstly transcellular where diffusion occurs through the
capillary endothelial cell wall; secondly, paracellular where they travel
in between the cells, and lastly vesicular where analyte transport occurs
from the cells to the ISF [45]. The interstitium is composed pre-
dominantly of a network of collagen, elastin, and glycosaminoglycans
[46]. ISF resides within this network transporting metabolites and
electrolytes to tissues, muscle cells, cartilage, bone cells, organs and
other cell groups [38].
While there are a number of interstitial regions throughout the body
[42], interest for wearable devices is within the dermal and sub-
cutaneous tissue compartments. Skin, the largest human organ, func-
tions to protect internal tissues and organs. It is made up of three
Fig. 1. Conceptualisation of a solid microneedle device worn on the human arm depicting the microneedles in the dermal interstitium and a simple representation of
an oxidase-enzyme electrochemical reaction occurring at the microneedle/interstitial-fluid interface resulting in electrochemical data being collected and transmitted
to a phone.
Fig. 2. Distribution of water in the human body showing the approximate vo-
lume of blood plasma and ISF in the extracellular fluid compartment, and the
volume of tissue and blood cells in the intracellular fluid compartment, adapted
from [39].
Fig. 3. Schematic representation of fluid flow to and from the interstitium,
adapted from [46,47].
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primary layers as can be seen in Fig. 4. The outermost layer of the
epidermis is the stratum corneum, which is made up of dead, keratin-
filled cells, embedded in a lipid bilayer. The stratum corneum is ap-
proximately 10–20 μm in thickness [48], this layer prevents water loss
from the body as well as acting as a barrier against external con-
taminants and environmental influences. Below the stratum corneum is
the viable epidermis which is rich in immunologically-active cells such
as Langerhans cells and is approximately 75–150 μm thick [49]. Finally,
the dermis, which ranges from 1 to 4 mm in thickness [50] is the main
structural connective tissue in the skin. The dermis is composed of fi-
broblasts, collagen fibres, elastic fibres, glyosaminoglycans, proteogly-
cans and is rich in blood and lymph vessels [49,51,52]. A real-time
histological image of the dermal interstitial region can be seen in Fig. 5
[53]. Dermal ISF occupies the extracellular spaces between the cells,
connective tissues and the vasculature. Both its location and its link
with the vasculature system has resulted in research efforts towards
developing extraction methods as well as attempts at understanding the
relationship between plasma and ISF in terms of analytical composition.
2.1. Brief history of ISF sampling
Standardized techniques to access ISF through the skin have not
been fully realised and represent something of a technical challenge.
There are a limited number of methods which have been applied to the
dermis for ISF extraction. One technique which continues to be applied
for research purposes is the suction blister fluid method which involves
the application of suction to the epidermal layer. This separates the
epidermis and the dermis, creating a space in which ISF collects.
Suction is then applied to the blister over time to collect the contained
fluid [55,56]. Some disadvantages associated with this procedure are
inflammation surrounding the blister, variations in blister size in ad-
dition to fluctuations in the volume of fluid collected [57]. Wick im-
plantation is another method which requires the use of suction, in this
instance blisters are not created; instead a nylon wick is firstly inserted
into the dermal space so that ISF can be extracted directly to the wick
[58]. Similarly, micropipettes have been used in conjunction with
suction to obtain nL volumes from the skin [59]. These methods can
result in discomfort to the patient as well as potentially providing in-
accurate measurements from forced capillary filtration [60]. Hypo-
dermic needles have also been applied 1.4 mm into the skin to extract
dermal ISF in an attempt to compare glucose levels in ISF and venous
blood. Extraction time was around 10 to 15 s. However, it yielded a
volume of only 0.5 μL, which is considerably lower than the standard
finger prick which yields up to 100 μL of capillary blood in seconds
[61].The ‘tissue cage reservoir’ was another method examined for col-
lecting dermal tissue fluid. The reservoir is made from a silicone based
tubing, with pinholes in the size range of 0–2 mm on either side. This
was implanted subcutaneously over a period of time until ISF built up in
the tubing. Bio-fluid collection via device implantation is not a feasible
practice for routine analysis of ISF [62]. The ‘skin window technique’,
involved scraping away the epidermal layer of the forearm and placing
a tissue culture chamber directly on to the dermal layer. Saline solution
is added to the chamber, and, after some time, a quantity of this fluid is
removed in order to introduce a negative pressure. This results in dif-
fusion of the extracellular fluid into the chamber; this method is quite
laborious, time consuming and un-suitable for clinical practice [63].
Venugopal et al. used near-IR laser to create micropores in the skin to
which they subsequently applied a vacuum to extract the fluid. As this
device penetrates the stratum corneum, it has been described as a
painless technique. However an extraction time of 6 h yielded a sample
volume of 60–90 μL [64]. Microdialysis and ultrafiltration are techni-
ques which have been used to sample ISF for therapeutic diagnostic
purposes. Both methods use a semipermeable membrane at the site of
interest. In the case of microdialysis, the drug molecules diffuse across
the membrane, whereas ultrafiltration applies a vacuum for extraction
of the drug molecules [28,65,66]. Microdialysis has proven to be suc-
cessful for drug monitoring at the site of interest and has been used in a
number of pharmacokinetic studies [67,68]. From the techniques
Fig. 4. Skin anatomy showing the outermost epidermal layer the epidermis, the
dermis and the subcutaneous tissue which is also known as the hypodermis,
adapted from [54].
Fig. 5. Dermal interstitial space imaged using confocal laser endomicroscopy illustration by Jill Gregory, [53] (Open access).
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described above, microdialysis has been the most successful in acces-
sing ISF for analytes that accurately represent the levels present in the
dermal tissue layer. Despite research efforts, there are no routinely
practiced clinical extraction procedures which sample transdermal fluid
for analysis, as a result, there is a limited amount of information on the
analytical composition of tissue fluid. Table 1 provides some examples
of target biomarkers which have been quantified in dermal ISF using
various analytical methods. Microneedle platforms which have been
developed to interface with ISF have become increasingly popular as a
potential platform for sampling tissue fluid from the dermis [30]
[69,70]. Further to this, through integration with electrochemical
sensors, they open up the possibility for wearable bio-chemical detec-
tion within the dermal interstitium [71,72].
3. Microneedles
The stratum corneum prevents permeation of large, charged, and/or
polar substances across the skin [74]. The microneedle transdermal
delivery device was developed to combat this problem by creating
transient micropores in the skin. These pores, the formation of which is
painless to the user, increase the permeability of the skin by several
orders of magnitude and close within hours [75–78]. Microneedles are
described as microscopic, spike-like projections, generally less than
1 mm in height, and arrays of which are fabricated using a wide range
of microfabrication techniques. The microneedle concept dates back to
1976 when a patent was filed on ‘puncturing projections’ by Gerstel and
Place [79]. It was 1998 before the first proof of concept was demon-
strated by Henry et al., whereby silicon microneedles were used to
deliver the drug calcein [80]. Whilst microneedles refer to a specific
type of device they have since been translated into a range of tech-
nologies for a variety of applications including cosmetic treatments
[81,82], drug and vaccine delivery [83,84] ocular drug delivery [85],
immunotherapy [86] electrophysiological sensing [87–89], ISF extrac-
tion [90] as well as bio-chemical sensing [91]. To the best of the au-
thors' knowledge, no microneedle platform is commercially available
for on-device ISF analysis. However there have been a few advances
towards the approval of microneedles as transdermal delivery devices,
for example, Nanopass technologies has received both CE marking and
510 k FDA approval for the Micron Jet which can deliver an influenza
vaccine [92,93]. In addition to this, 3M, who have a cGMP manu-
facturing facility are currently involved in a phase III clinical trial with
Radius health [94,95]. Solid microneedles produced by Seventh Sense
Biosystems have also received FDA clearance and CE marking for a
capillary blood sampling device using microneedles [71,96]. Table 2
depicts the current status of a number of microneedle technologies for
various applications.
3.1. Fabrication and classification of Microneedle's towards ISF analysis
Detailed descriptions of several microneedle fabrication methods,
materials used as well as information surrounding the classification of
these devices are provided in number review articles [85,101–105].
Microneedles are most commonly fabricated from silicon, metals and
polymers, however, ceramics, hydrogels, glass and composite based
microneedles have also been reported [106,107]. Hollow, dissolvable,
solid, coated and porous needles are examples of microneedle types
cited in the literature [105]. Here, we will mention a number of fab-
rication technologies which have been used to produce microneedles
specifically for ISF analysis. Both hollow and solid microneedles have
been produced to interface biosensors with dermal tissue fluid. Silicon
microneedles can be produced using a combination of common mi-
crofabrication processes (Fig. 6 A): photolithography, deep reactive ion
etching, wet etching and plasma enhanced chemical vapour deposition
(PECVD) [108,109]. This method of fabrication offers the possibility for
wafer-scale production of microneedle devices [110] as well as the
capabilities to fabricate both solid and/or hollow microneedles. Silicon
is a well-established material used in both nano and micro fabrication
processes where metal-oxide-semiconductor circuit technology can be
used to enable device functionality [111]. Despite such advantages, the
complex and timely nature of silicon processing as well as the cost of
equipment has resulted in research efforts towards more cost effective
microneedle fabrication methods such as drawing lithography and
micromolding [112–118]. Chen et. al recently fabricated microneedles
using a drawing lithography technique which incorporated magnetic
particles in a polymer mixture. Through application of a magnetic field
a 3D polymer structure is drawn away from the planar polymer surface
(Fig. 6 B) [119]. This process can be carried out in one step and does
not require expensive equipment [120], however further processing
steps are required towards biosensor construction.
Other approaches such as cutting and machining of needles and
attaching them via adhesion to a 3D printable [30] or a polymeric
[121] base have also been described in the literature; whilst this is a
straight forward and inexpensive approach, it is not easily scalable to
high volume manufacturing. UV rapid prototyping is a technology
which has successfully fabricated class II-A biocompatible hollow
polymeric microneedles. This technique uses computer models to 3D
print polymeric builds by guiding light over a photocurable material for
selective polymerization [122]. Once the device has been electro-
polymerised it is subject to a cleaning step prior to curing. The steps
involved in building 3D prototypes are few in comparison to the pro-
duction of silicon (see Fig. 7 A) [123]. Solid polymeric microneedles are
commonly fabricated from molding methods such as injection molding
and micromolding. Generally speaking, the injection molding process
Table 1
A summary of constituents which have been measured in ISF, their typical concentration levels, the sampling method applied and the quantification techniques
[20,55,61,64,73].
ISF constituent Measured concentration Typical concentration
rangesa
Sampling technique Quantification technique Subject tested
Glucose 4–8 mM 4.5–8 mM Hypodermic needle Manual hexokinase method (Human n = 17)
Cholesterol < 5.1 mM 1–5 mM Microneedles Commercial cholesterol kit Mouse (n = 1)
Cortisol 24–40 nM Morning: 1–50 nM Near-IR laser & vacuum
pressure
ELISA & Electrochemical Impedance spectroscopy Human (n = 6)
Afternoon: 27–42 nM
Lactate 1.17 ± 0.23 mM 1–2 mM Microdialysis Immobilized enzyme sensor technology (YSI 2700
Select)
Human (n = 15)
Lipids 1.5 ± 0.3 μM Not reported Suction blister LC-Mass spectrometry Human (n = 18)
Na+ 141 mM 135–150 mM Suction blister Glass Capillary Gas Chromatography-Mass
Spectrometry
Human (n = 9)
K+ 4.4 mM 3.8–4.9 mM Suction blister Glass Capillary Gas Chromatography-Mass
Spectrometry
Human (n = 9)
Cl− 110 mM 99–117 mM Suction blister Glass Capillary Gas Chromatography-Mass
Spectrometry
Human (n = 9)
a Typical concentration ranges for healthy individuals at rest.
J. Madden, et al. Sensing and Bio-Sensing Research 29 (2020) 100348
4
involves heating a material to its melting temperature Tm and subse-
quently adjusting the processing temperature in order to inject the
material into a mold at a given speed. Although injection molding
equipment are expensive they are compatible with large scale manu-
facturing [124,125]. Polycarbonate microneedles have been produced
via injection molding at a production time of 12 s per sample proving to
be appropriate for scalable manufacturing [125]. Micromolding
methods employ solid microneedle structures to fabricate an inverse
mold which is often formed from an elastomer [112]. This mold is then
used to cast materials such as gold inks, polymers, composites or mix-
tures of materials [112–114,126] with biomolecules required for de-
tection (see Fig. 7 B) [127] [114]. Once the material is applied to the
mold, it can be subject to an external force such as centrifugal forces,
compression or vacuum which are applied to ensure the mold cavities
are filled. The material is then cured and allowed to cool prior to se-
paration from the mold. In comparison to other fabrication methods
this technique is relatively in-expensive, involves less complex proces-
sing steps and few equipment requirements.
Specific to ISF analysis, microneedles can be broadly summarised
into two categories, firstly those used to extract or sample ISF for
subsequent analysis and secondly those used to interface the ISF with
on-device sensor technologies. As previously noted, this review is fo-
cused on electrochemical sensors fabricated on microneedle platforms.
However it is important to note that other sensing modalities such as
optical detection have also been integrated with these devices [129]. In
many cases, microneedles fabricated specifically for ISF sampling have
been used with the assistance of microfluidics or diffusion assisted
methods in order to interface ISF with an analytical tool, where ex-
amples of these can be seen in Fig. 8 A–C [27,30,60,130]. Those fab-
ricated for on-device sensing commonly require further processing post
fabrication. Hollow microneedles have been integrated with common
electrode materials i.e. gold, platinum and carbon by embedding wires
of metal or carbon pastes into the needle bore prior to biosensor con-
struction (see Fig. 8 D–F). Solid microneedles, on the other hand, have
been metallised directly using techniques such as e-beam evaporation
and sputtering followed by biosensor modification steps or in some
instances the needle material itself has been molded with the necessary
biological recognition element (see Fig. 8 G–I).
3.2. Microneedles for ISF extraction
In an earlier section of the review, a number of ISF sampling tech-
niques were described, here, we will provide a few examples of where
microneedles have a been applied to extract tissue fluid for analytical
measurements. Hydrogel forming microneedles have been inserted into
skin where they swell as a result of ‘fluid uptake’. The patches were
worn for various time periods (30 min up to 3 h) after oral dosing of
caffeine or glucose. Caffeine levels were measured using HPLC and a
standard glucose assay kit was used to quantify glucose concentrations.
Whilst this study proved that hydrogel microneedles could be used to
sample ISF as well as detect the presence of both caffeine and glucose,
analytical levels measured did not correlate with plasma levels and a
number of lengthy laboratory procedures were required [132]. Samant
et al. have also demonstrated successful ISF collection with micro-
needles, where over 1 μL of tissue fluid was collected within 20 min
from both pig cadaver skin and living human subjects. Similar to
sampling techniques discussed in Section 2.1, these long extraction
times and low volumes are not compatible with current medical prac-
tices [138,139]. Miller et al. successfully extracted ISF (up to 20 μL)
from human subjects for proteomic and transcriptomic analysis. ISF
flow to the collection capillary took 30–120 s followed by a further 10
to 15-min for 20 μL of the fluid to collect. In comparison to extraction
methods discussed earlier, this technique allowed for extraction in less
than 20 min, in addition to this, a larger quantity of ISF was obtained.
Proteome and transcriptome information was acquired showing simi-
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used as an alternative bio-fluid for protein analysis [30]. Although these
volumes are higher than those listed previously they are still relatively
low in comparison to quantities of saliva, sputum, blood and urine
routinely collected for examination. Applying sensors directly to the
site of interest has the potential to eliminate the need for extraction
and/or handling of tissue fluid. Currently, CGM devices are the only
commercially available skin worn wearable device capable of on-device
monitoring in tissue fluid. This technology contains a sensor which can
penetrate up to 5 mm in to the skin [140]. In comparison, microneedles
integrated with electrochemical sensors have been reported at heights
ranging from a couple of hundred microns up to 1.5 mm [112,141],
with some studies indicating that heights of less than 1000μm are re-
commended for a more pain free user experience [142].
3.3. Hollow microneedles for electrochemical sensing applications
Whilst still at a relatively immature stage of development, micro-
needles fabricated and modified with electrochemical biosensor sur-
faces have demonstrated significant potential for on-device detection
and/or monitoring of analytes present in tissue fluid. In order to
functionalise hollow microneedles for electrochemical sensing, the
lumen or bore of the microneedle can be modified to contain common
electrode materials such as carbon, platinum and gold for subsequent
functionalisation with biomolecules. A correlation found between blood
and interstitial fluid alcohol levels has led to an interest in transdermal
alcohol detection [143] using hollow microneedles fabricated from a
liquid crystal polymer. 100-μm diameter wires were applied through
Fig. 6. A Fabrication sequence of the 3-electrode non-enzymatic microneedle-based glucose sensor (a) deep reactive ion etching of silicon to form rectangular pillar
array; (b) wet etching of the rectangular pillar Si array to make sharp Si needle array; (c) iron deposition through a shadow mask and MWCNT growth followed by
electroplating Pt nano-particles; and (d) Ag deposition through a shadow mask and formation of Ag/AgCl reference electrode, [108] (Open access), B (a1–4)
Formation process of liquid MA using MDL method. (b, c) Magnetic field distribution in the liquid, [119] (Reprinted by kind permissions of and ACS publications).
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the needle bore, an illustration of these was seen in Fig. 8 E. Platinum
wire, which is a biocompatible material, was used for both the counter
and working electrodes and silver wire was employed as the reference
electrode. Alcohol oxidase, the biomolecule required for detection, was
deposited with chitosan on an o-phenylinediamine modified platinum
working electrode. O-phenylinediamine can reduce interference from
other common interfering species such as acetaminophen and L-ascorbic
acid. Chitosan was used to immobilise/entrap the alcohol oxidase
(AOx) on to the electrode surface. When producing sensors for direct
contact with ISF, it is important that molecules do not leach from the
device in to the microvasculature system. To prevent leaching of the
alcohol oxidase enzyme a final modification of Nafion was deposited.
Detection studies were carried out on artificial skin models and within
artificial ISF (Table 3). Monitoring times of up to 100 min were
achieved. A three electrode configuration on the microneedle platform,
demonstrated on-device sensing capabilities, without the need for
conventional reference and counter electrodes [134].
Hollow microneedles have also been fabricated to form part of a
wearable device for melanoma detection [145]. A catechol-coated
carbon-paste was embedded in the bore of one microneedle to function
as the working electrode. Carbon paste was embedded in another
needle to function as a counter and Ag/AgCl ink was inserted into the
third microneedle as the reference electrode. The microneedles function
to detect tyrosinase, an enzyme whose sensitivity is significantly in-
creased in the case of primary melanoma. Catechol is oxidised to ben-
zoquinone (BQ) following its interaction with tyrosinase resulting in the
reduction of the BQ product. This reduction is measured amperome-
trically at the printed carbon working electrode as can be seen in Fig. 9
(D–F) [145]. Similar to the previous study, phantoms were used in an
attempt to replicate the ISF and skin environment in order to assess the
sensor response in a complex media. The majority of research articles
discussed through-out this section focus on microneedle sensor
developments with a bench top potentiostat which uses conventional
electrochemical measurement methods. In order for a microneedle
sensor to become a wearable, it must be integrated with the necessary
electronic components. This study used a flexible electronic board to
control the electrochemical measurements and data transmission.
Whilst this device is solely suitable for single-use applications, it offers
prospects towards cost effective wearable cancer screening technolo-
gies.
Hollow microneedles have also been combined with ion-selective-
electrodes (ISE) for potassium detection. Electrolytes are attractive as a
target for microneedle sensors as fluctuations in concentration levels
can result from factors such as exercise, diet, disease and organ failure
[146]. Here the ISE (composed of either porous carbon or porous gra-
phene) was placed directly under a hollow microneedle. A microfluidic
chip was used to extract fluid through a channel, towards the solid-state
ISE where potassium levels were measured. Results showed that normal
physiological potassium concentrations could be measured in the pre-
sence of interfering ions in standard solutions of known concentration.
This technique required the use of vacuum and microfluidic valves as
the sensor was embedded below the needle bores resulting in delayed
measurements [146]. So far, we have seen that hollow microneedles
combined with embedded electrochemical sensors can detect metabo-
lites, cancer markers, and electrolytes, another significant example is
drug detection. Levodopa (L-dopa) - a drug used in the management of
Parkinson's disease has recently been measured with a wearable mi-
croneedle platform [141]. Optimizing L-dopa dosage is often dependent
on a description of symptoms provided by patients which can be pro-
blematic towards appropriate treatment regimes. On this platform, two
microneedles were modified to produce two working electrodes. One
lumen was packed with a mixture of graphite paste, mineral oil and the
enzyme tyrosinase to function as an enzymatic sensor for L-dopa de-
tection (Fig. 10 B, E and H). The second working electrode contained a
Fig. 7. A Needle array basin design followed by 3D printing of the design using a Form 2 SLA printer, adapted from [128], (Open access), B Schematic showing the
preparation of silk fibroin microneedles: (A) schematic process of preparing needles, (B, C) images of 15 × 15 array produced via micromolding [127] (Reprinted by
kind permissions of and ACS publications).
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mixture of graphite paste and the mineral oil for non-enzymatic de-
tection of L-dopa (Fig. 10, A, C and F). This dual sensor approach
presents improved information gathering capabilities as well as a
method of monitoring a second drug carbidopa. Measurements were
carried out for up to 100 min demonstrating the potential for con-
tinuous drug monitoring. Appropriate concentration levels could be
detected within artificial ISF through ex-vivo skin (Fig. 10 D) as well as
phantom gels (Fig. 10 F), indicating suitability for further clinical
evaluation [141]. Currently no data exists on L-dopa diffusion from
blood to ISF; however it is thought that the short half-life of drug mo-
lecules could create problems for ISF drug monitoring as rapid fluc-
tuations in drug concentrations can occur post administration [45].
Simultaneous screening on the one microneedle platform is also an
attractive vision for future wearables. Hollow microneedles have been
constructed for the simultaneous detection of vital diabetes markers:
ketones, glucose and lactate. Ketone monitoring is required for the di-
agnosis of a life threatening condition, diabetic ketoacidosis.
Conventionally, this is achieved through capillary measurement of β-
hydroxybutyrate. At present there is no information on β-hydro-
xybutyrate levels in ISF; however, based on its small molecular size, it is
thought to be close to that of plasma levels. CNC-machined hollow
needles have been packed with carbon paste and later modified towards
analysis of β-hydroxybutyrate, glucose and lactate. The modified bio-
sensor layers for ketone and glucose detection are depicted in Fig. 11.
This study detailed successful efforts to assess the sensor in a protein
modified artificial ISF recipe over a prolonged period of 300 min [147].
There has been tremendous focus on developing various types of
non-invasive wearable glucose monitoring systems on mouth guards,
contact lenses and wearable sweat sensor patches to name a few
[148–152]. A number of reviews have been published focusing pri-
marily on microneedles for glucose detection [153–155]. Jina et al.
demonstrated the use of hollow microneedles for true ISF glucose
measurements. ISF diffused passively from the skin through the needle
bore to a sensor housed underneath the needles. An image of this device
was shown in Fig. 8 D [133]. A mean absolute relative difference of
15% was reported between ISF and capillary blood glucose levels. Si-
milar to the platform discussed for melanoma detection, this device was
assembled to contain the potentiostat circuit, a microprocessor to dis-
play and save the data and a battery. In this instance data were
downloaded from the device as opposed to a wireless transmission. Up
until now, each of the studies conducted measurements with
Fig. 8. Images A–C [129,131,132] depict microneedles which have been applied for ISF fluid extraction and subsequent analysis, (Reprinted by kind permissions of
ACS publications, Plos one & Springer Nature) Images D–F [133–135] are hollow microneedles which have been integrated with electrochemical based sensors
towards detection or monitoring within ISF, (Reprinted by kind permissions of Sage Journals, Elsevier & Springer Biomedical microdevices) and images G–I
[113,136,137] show solid microneedles which have been modified through coating technologies and biosensor construction steps so that sensing or monitoring can
be carried out at the interface between the solid microneedle and ISF, (Reprinted by kind permissions of ACS publications, Elsevier and the Electrochemical Society).
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microneedles in buffer based solutions, artificial ISF, ex-vivo skin and in
some instances phantom gels. This is one of few examples whereby a
hollow microneedle patch is conducting electrochemical detection
within a real ISF environment.
3.4. Solid microneedles for electrochemical sensing
Direct modification and functionalisation of solid microneedles with
electrode materials is another approach for developing on-needle
electrochemical sensors. This approach eliminates the need for packing
micron sized bores with pastes and/or wires for front to back needle
connection. Instead, techniques such as e-beam evaporation and sput-
tering can be used to form electrodes and interconnection tracks on the
needles with the help of masking methods to ensure reproducible
electrode fabrication. Sharma et al. have developed a glucose sensor on
injection molded polycarbonate based microneedles. Four microneedle
arrays were formed, three were metallised with Pt, one of which was
used as a counter and the final array was metallised with silver to
function as a reference electrode. The remaining platinum electrodes
were modified via electropolymerisation of a glucose oxidase (GOx)/
polyphenol mixture to produce two working electrodes. The device was
capable of detecting glucose concentrations in buffer based solutions at
physiologically relevant levels for ISF analysis (0-30 mM), with a re-
sponse time of 15 s [156]. Entrapment is a common enzyme im-
mobilisation strategy used in the development of microneedle devices,
so as to physically restrict the enzyme from leaching. Further work
evaluated its use as a wearable glucose sensor on human volunteers
with Type 1 diabetes, in addition to healthy control patients. The in-
tradermal measurements (Fig. 12) obtained from two working elec-
trodes indicate comparable results between ISF and blood glucose
measurements [35]. Testing was carried out for up to 20 h, with a lag of
no more than 15 min. These results are promising towards the appli-
cation of microneedles for continuous glucose monitoring; however, the
durations of testing reported are not close to that of current CGM's
which can function for 6–14 days [157].
Other investigations have taken a similar approach towards glucose
detection on solid microneedles. Barrett et al. have fabricated solid
electrochemical microneedles by implementing a low-cost micro-
molding polymer replication approach (as discussed in Section 3.1) for
mediated glucose detection, using gold metallised microneedles as the
working electrode, an external Ag/AgCl reference and a Pt wire as a
counter electrode [137]. This work was furthered to conduct on-device
glucose measurements by incorporating three electrode arrays on the
one microneedle platform. However, this work is at preliminary stages
with demonstrations of buffer based glucose detection at appropriate
levels for ISF (0–19.5 mM) [126]. Attempts at non-enzymatic glucose
sensors have also been demonstrated on solid stainless steel micro-
needles. These were modified with platinum and nafion for the direct
electrochemical detection of glucose. Removal of the enzyme from the
sensor surface allows for a more facile fabrication process avoiding the
need to immobilise a biomolecule onto the needle surface post fabri-
cation. This approach eliminates any risks associated with biomolecules
leaching from the solid needles as well as reducing the biosensor con-
struction costs. A linear response within the physiologically relevant
ranges (1–40 mM) was achieved in buffer based solutions; however, this
set-up employed an external Ag/AgCl RE and a Pt coil as the counter.
Whilst successful glucose detection was achieved in blood samples, a
40% decrease in activity was reported after 12 continuous measure-
ments proving to be disadvantageous towards continuous glucose
monitoring applications [158]. Windmiller et al. developed the first
solid polymer based microneedle tool capable of detecting both gluta-
mate and glucose, with the potential for in-situ analysis. Glutamate, an
excitatory neurotransmitter, is implicated in a number of medical
conditions including heart attacks, strokes, and brain injury [159]. Both
solid and hollow microneedles were fabricated using a rapid proto-
typing system. The hollow microneedles were used to mask all of the
metallized regions on the solid microneedle substrate (Fig. 13 A and B),
exposing only the microneedle metallic tips as sensor regions.
Here, the glutamate oxidase (GluOx) was immobilized via dip
coating and GOx was immobilized using electrodeposition with both
techniques entrapping the enzymes in o-phenyline diamine (Fig. 13 C).
Measurements carried out in both phosphate buffers and undiluted
Fig. 9. Feasibility of transdermal tyrosinase screening in skin phantom gel using microneedle sensor. A Actual image of carbon paste packed hollow microneedle in
comparison with a penny; scale bar = 1 cm. B Schematic of the pyramidal structure of the carbon filled microneedles surface with WE, CE, and RE. C Actual
experimental setup mimicking skin phantom gel and microneedle used for tyrosinase detection with integrated electronic board. Amperometric response of different
tyrosinase concentrations: D 0.25, E 0.5, and F 1 mg mL−1, before (black line) and after (red line) interaction with skin phantom gel; G relative current values
obtained from D to F amperogram, [145] (Reprinted by kind permissions of Wiley). (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
J. Madden, et al. Sensing and Bio-Sensing Research 29 (2020) 100348
9
human serum samples indicated that the sensor was stable for up to 8 h
and could function in complex bio-fluids; however no information was
provided surrounding the plasma/ISF glutamate relationship [160].
Another metabolite receiving interest for microneedle sensors is lactate
as it is often monitored for diseases such as cancer, obesity and diabetes
[161]. It has also been a target of interest in the field of sports science
[162,163]. Little data exists on the correlation between lactate levels in
plasma and ISF, yet, its low molecular weight and high diffusivity in-
dicate that concentration levels should be similar [45]. In work carried
out by Caliò et al., polymer based microneedles were fabricated using
photolithography methods whereby the enzymes lactate oxidase (LOx)
and GOx were incorporated into a photocurable mixture [161]. Both
lactate and glucose were amperometrically detected in buffer based
solutions. The needles were molded from a material/biomolecule
mixture reducing the need for additional functionalisation steps. This
study showed a proof of concept with an external reference and counter
as opposed to an on-device approach; however results were not entirely
within the clinically relevant concentration ranges of 0.5–5 mM [164].
Another example of a lactate microneedle biosensor was developed by
Bollella et al. [34,165] whereby polycarbonate microneedles were
metallized with gold as the working electrode and an external reference
was used for experimentation. The working electrode was functiona-
lized via electrodeposition of gold multiwalled carbon nanotubes, fol-
lowed by an electropolymerisation with methylene blue, and finally
chemical attachment via drop casting of the enzyme. This device was
found to function within a linear range of 0 to 100 μM in solutions of
artificial ISF as well as human blood serum [165]. Again these levels are
not within the appropriate ranges for lactate measurements. A decrease
in signal was observed for measurements conducted in human serum
which can be expected considering a higher level of fluid complexity. It
is well known that biofouling is a common phenomenon for electrodes
interfacing with bio-fluids, and despite lower levels of protein existing
in ISF, tests in human serum provide insight into potential fouling ef-
fects. This needle technology has also been functionalised towards
monitoring β-lactam (penicillin) levels. Preliminary data was obtained
during 5 h intradermal measurements from human volunteers with
results demonstrating a similar pattern to penicillin levels measured in
blood as well as within microdialysate samples (see Fig. 14) [116].
Microneedles fabricated using the magnetorheological drawing
technique discussed in Section 3.1 demonstrated simultaneous detec-
tion of uric acid, glucose and cholesterol in spiked serum samples. No
indication regarding the Plasma/ISF analyte relationship was provided
Fig. 10. A Square-wave voltammograms for Levodopa in ISF from 50 to 250 μM concentrations in 50 μM increments. (Inset shows the calibration plot of the
background-subtracted peak-current vs L-Dopa concentration). B Chronoamperometry responses of the L-Dopa biosensor recorded in ISF from 50 to 250 μM in 20 μM
increments at 0.3 V vs Ag/AgCl electrode. (Inset shows the corresponding calibration plots.) C, E Real-time L-Dopa detection in artificial ISF through the mice skin-
penetrated microneedle. F, H SWV and amperometric responses of different L-Dopa concentrations with the mimicking-skin phantom gel. D Schematic showing the
detection of L-Dopa in artificial ISF using the microneedle penetrated through the mice skin. G Schematic representation of the mimicking-skin phantom gel with the
penetration of the microneedle, [141] (Reprinted by kind permission of ACS publications).
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for any of the analytes; however, this work demonstrated portable si-
multaneous sensing capabilities on one microneedle platform with a
portable electroanalyser [136]. As previously mentioned, few articles
detail efforts to integrate microneedle electrochemical sensor platforms
with the necessary electronics to perform measurements without a
bench top potentiostat. One recent example of wireless glucose detec-
tion within human serum was demonstrated using solid microneedles.
The sensor was assembled with a miniaturised potentiostat for elec-
trochemical measurements, an analog to digital convertor module,
Bluetooth and a near-field communication (NFC) module as well as a
miniaturised flexible battery [117]. It demonstrated significant poten-
tial as an integrated wearable platform capable of measuring bio-che-
mical signals and transmitting data in a readable format. However, si-
milar to the majority of studies discussed, it was not subject to testing in
the human dermal interstitium. The following tables provide a sum-
mary of recently published electrochemical based microneedle sensors
fabricated from micromolding (Table 4), injection molding (Table 5)
and other miscellaneous methods (Table 6) detailing the microneedle
type, materials and biosensor layers a long with the concentrations
ranges measured and those that are physiologically relevant.
4. Challenges and future perspectives
Significant advances have been made towards accessing and ana-
lysing dermal tissue fluid, yet, limited information exists for physiolo-
gically relevant ranges of analyte and drug concentrations. This in-
formation is vital towards diagnosing health conditions and
physiological states. Much of the work carried out to date has been on
the major metabolite glucose [168,169]. Further investigations into the
clinical chemistry of tissue fluid may present other biomarkers of in-
terest in ISF, as well as providing further insight into the current un-
derstanding on how biomarker tissue fluid levels relate to those of
blood. ISF sampling practices can be time consuming with some of the
more recent microneedle extraction studies showing times of 10 to
15 min to attain sufficient levels of fluid for analysis [30]. Furthermore,
sampling methods collect relatively low volumes of the extracellular
fluid. Extraction tools such as microneedle arrays and sonophoretic
devices often require the use of a vacuum or suction to enhance per-
meability through the tissue matrix. These methods can result in patient
discomfort as well as forced capillary filtration leading to inaccurate
measurements [60]. Utilizing passive diffusion methods is far more
desirable for direct sensing applications. For example Miller et al. col-
lected ISF at volumes of up to 20 μL, without the need for a vacuum or
Fig. 11. Schematic representation of dual-marker HB/GL sensing on microneedle sensor platform. SEM image of the CNC-fabricated UCSD microneedle showing
2 × 2 array of hollow microneedles. The optical image of the microneedle sensor, showing the HB WE packed with GP/IL/PD, along with the GL WE filled with GP/
MO paste and another GP/MO packed microneedle acting as the CE. An Ag/AgCl wire (500 μm)-integrated microneedle acts as the RE. The schematic illustration of
the dual-analyte amperometric detection mechanism on multilayer modified sensors for HB (left) and GL (right). Also shown are typical amperograms obtained for
HB (left) and GL (right) detection, [147].
Reprinted by kind permission of ACS publications.
Fig. 12. Double axis plot representing chronoamperometric measurements
from two sensors (black: working electrode 1; red: working electrode 2) on the
same device versus glucose measurements from venous blood (blue stars), [35].
(For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
Reprinted by kind permission of The Royal Society of Chemistry.
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suction mechanism [30]. Needles which create a concentric opening
around the needle are thought to minimize dermal compaction at the
site of insertion preventing displacement of ISF from the skin [154].
Lag time is another challenge to consider. A number of studies have
contributed to an understanding of the perfusion time of glucose from
the blood to the ISF [170–173] with various lag times reported in the
literature ranging from 5 to 25 min [173,173]. Lag time is not well
studied for other target molecules mentioned through-out this review,
however, advances in sensing technologies may in fact lead to answers
on specific plasma-to ISF lag times. For example, Venugopal et al. de-
veloped a sensor capable of measuring alcohol levels in tissue fluid with
reports of a lag time of less than 12 min between the blood and inter-
stitial alcohol sensor readings [143].
Whilst significant advances have been made towards efficient fab-
rication of microneedles with common electrode materials, con-
structing biosensors on electrodes is not a straight-forward practice.
These lab scale modification methods are not aligned with efficient
device fabrication methods. In addition to this, sensor stability, sensor
degradation, bio-fouling and biocompatibility are amongst some of the
challenges faced by an electrochemical microneedle sensor surface. In
the case of solid needles, biomolecules on the sensor surface should be
entrapped/immobilized or protected by biocompatible materials to
prevent leaching of biomolecules into the dermis [134]. In the case of
biomarkers such as hormones, DNA and proteins, a number of steps are
required in order to achieve detection as well as longer waiting times
and this type of approach is not compatible with continuous monitoring
applications [174–176].
At this time there is limited data on the safety and efficacy of mi-
croneedles integrated with electrochemical sensors. In a study de-
scribed earlier in this review by Jina et al., skin was examined for er-
ythema and edema following microneedle removal. No irritation was
visible several days after array removal [133]. Other observations
concur, and indicate that the transient erythema typically reported
[89,177] after application of microneedle arrays to the skin tends to
fade within a relatively short period, i.e. minutes to hours.
Almost all of the experiments presented throughout this review used
a bench top potentiostat to conduct conventional electrochemical de-
tection of analytes. In order for a microneedle sensor to find its way into
Fig. 13. (A) Solid and hollow microneedle constituents of the bi-
component microneedle array electrode. (B) Fully-assembled bi-
component microneedle array electrode. (C) Growth of the glutamate
oxidase (GluOx)-functionalized poly(o-phenylenediamine) (PPD) film
at the solid microneedle surface within the recess from the o-pheny-
lenediamine (o-PD) monomer. (D) Biocatalytic behavior of the elec-
tropolymerized glutamate oxidase–poly(o-phenylenediamine) film (il-
lustrated in purple), enabling the quantification of glutamate levels
within the transdermal fluid, [160] (Reprinted by kind permission of
Wiley). (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
Fig. 14. A Image of individual wearing the microneedle array which consists of four metallized sets of microneedles, three coated with gold and one (bottom right-
hand side in photo) with silver B in-vivo response of three β-lactamase biosensors applied to a healthy volunteer (red, green, and dark blue traces). Control response
has been subtracted from each trace to remove effects of drift. Light blue: Dialysate levels of penicillin-V from a microdialysis probe inserted subcutaneously in the
forearm (samples taken every 15 min), Pink: Serum levels of penicillin-V measured from blood samples taken every 15–30 min (All measurements were time aligned),
[116]. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Reprinted by kind permission of ACS publications.
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a wearable patch implementation, one must develop a measurement
algorithm suitable for low power consumption. With advancements in
battery technology, usage of low power electronic components and low
power wireless communication protocols, this appears to be a feasible
milestone. However, as many of these devices are at an immature stage
of development few articles have focused on the research efforts needed
to integrate electrochemical sensor platforms with the necessary elec-
tronics.
5. Concluding remarks
The opportunity to attain real time molecular information from ISF
remains a challenge for wearable devices. Further studies on the
transdermal fluid composition as well as the molecular perfusion time
from blood to the dermal ISF in human subjects is necessary for the
development of future transdermal sensors. Significant advances have
been made towards constructing electrochemical biosensors on micro-
needle platforms demonstrating their ability to gather clinically re-
levant information. Pharmaceuticals, metabolites and electrolytes are
examples of targets which have been successfully detected with elec-
trochemical microneedle devices in artificial ISF media as well as in
human serum samples. This is the first step towards developing the
sensor component for intradermal molecular monitoring. Integrated
microneedle sensors have not yet reached a mature stage of develop-
ment, however, a number of devices have been tested in preliminary
clinical evaluation studies on human subjects. Furthermore, a select few
have integrated microneedle sensors with a miniaturised potentiostat, a
communication module and a power source. These devices demonstrate
considerable promise for the future of wearable molecular monitoring
for both personal and on-patient health care.
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